Advertisement

Zellkinetische Grundlagen und immunologische Aspekte der Zytostatika-Therapie

  • G. A. Nagel

Zusammenfassung

Bei der Planung einer Chemotherapie wird heute die Art und Verabreichungsform von Zytostatika nicht allein aufgrund ihrer pharmakologischen Eigenschaften und biochemischen Wirkungsmechanismen gewählt. Vielmehr gilt es, beim Aufstellen eines Chemotherapieplanes drei Variable, die sich gegenseitig beeinflussen können, aber nicht müssen, zu berücksichtigen:
  • die Pharmakokinetik der Zytostatika

  • die Zellkinetik normaler und neoplastischer Gewebe

  • die Immunokinetik von Wirt-Tumor-Beziehungen.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. ANDREWS, J.R.: Combined cancer radiotherapy and chemotherapy: The relevance of cell population kinetics and pharmacodynamics. Cancer Chemother. Rep. Part 1, 13, 313 (1969)Google Scholar
  2. BASERGA, R. (ed.): The cell cycle and cancer. New York: Marcel Dekker 1971Google Scholar
  3. BURCHENAL, J.H.: Clinical parameters of combination chemotherapy. Meth. Cancer Res. 10, 3 (1973)Google Scholar
  4. CARTER, S.K.: Clinical trials and combination chemotherapy. Cancer Chemother. Rep. Part 1, 55, 81 (1971)Google Scholar
  5. CHABNER, B.A., MYERS, C.E., COLEMAN, N., JOHNS, D.G.: Clinical pharmacology of antineoplastic agents. New Engl. J. Med. 292, 1107, 1159 (1975)PubMedCrossRefGoogle Scholar
  6. DE VITA, V.T.: Cell kinetics and the chemotherapy of cancer. Cancer Chemother. Rep. Part 1, 55, 23 (1971)Google Scholar
  7. FREI, E. III: Effect of dose and schedule on response. In: Cancer medicine. HOLLAND, J.F., FREI, E. III (eds.), p. 717. Philadelphia: Lea & Febiger 1973Google Scholar
  8. HALL, T.C.: Limited role of cell kinetics in clinical cancer chemotherapy. In: Nat. Cancer Inst. Monogr. 34, p. 15. US Department of Health, Education and Welfare, National Cancer Institute, Bethesda (Maryland) 1971Google Scholar
  9. HALL, T.C., KARRER, K.: Cancer chemotherapy - dose schedules and combinations. Wien: Verlag der Wien. Med. Akademie 1968Google Scholar
  10. KLEIN, H.O., LENNARTZ, K.J.: Chemotherapy after synchronization of tumour cells. Sem. Hematol. 11, 203–227 (1974)Google Scholar
  11. MATHÉ, G. (ed.): Scientific basis for cancer chemotherapy. Recent Results in Cancer Research. Vol. 21. Berlin-Heidelberg-New York: Springer 1969Google Scholar
  12. NAGEL, G.A.: Theorie und Praxis der Systemtherapie des Krebses. Wien. med. Wschr. 692 (1972)Google Scholar
  13. REGELSON, W.: Immunologie factors and chemotherapy. In: Cancer chemotherapy. Vol. II. BRODSKY, I., KAHN, S.B. (eds.), p. 69. New York: Grüne & Stratton 1972Google Scholar
  14. SADOFF, L.: Mechanisms of action of cancer chemotherapy drugs: An alternative hypothesis based on inhibition of immunologic function. Cancer Chemother. Rep. Part 1, 56, 559 (1972)PubMedGoogle Scholar
  15. SALMON, S.S., JONES, S.E. (eds.): Adjuvant therapy of cancer. Amsterdam- Oxford-New York: North-Holland Publ. 1977Google Scholar
  16. SKIPPER, H.E., SCHABEL, F.M.: Quantitative and cytokinetic studies in experimental tumor models. In: Cancer medicine. HOLLAND, J.F., FREI, E. III (eds.), p. 629. Philadelphia: Lea & Febiger 1973Google Scholar
  17. STEEL, G.G.: Cytolinetics of neoplasia. In: Cancer medicine. HOLLAND, J.F., FREI, E. III (eds.), p. 125. Philadelphia: Lea & Febiger 1973Google Scholar
  18. STEWART, T.H.M., KLASSEN, D., CROOK, A.F.: Methotrexate in the treatment of malignant tumors: Evidence for the possible participation of host defence mechanisms. Canad. med. Ass. J. 101, 191 (1969)PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin · Heidelberg 1979

Authors and Affiliations

  • G. A. Nagel

There are no affiliations available

Personalised recommendations